Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum- -lactamase-producing Gram-negative organisms
Authors:
Open Access
- 11 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (7) , 1510-1513
Abstract
Infections with extended-spectrum-β-lactamase-producing organisms are an increasing public health concern. We reviewed the use of an outpatient parenteral antibiotic therapy (OPAT) programme to facilitate the early discharge from hospital of patients with ESBL-associated urinary tract infections. A retrospective review of patients treated for urinary tract infections caused by ESBL-producing organisms through the OPAT programme at the Royal Hallamshire Hospital, Sheffield, UK over a 4 year period to January 2010 was conducted. Data on patient demographics, clinical presentation and laboratory results were collected. Twenty-four OPAT episodes involving 11 patients were identified. Six patients (54.5%) had an underlying urological abnormality on presentation to OPAT. All patients were treated with parenteral ertapenem. Two patients had multiple infections treated by OPAT. The mean duration of the OPAT episodes was 9.9 days (range 3–42). A total of 238 inpatient bed days were avoided, with resultant cost savings. Ertapenem administration through OPAT may help to decrease the costs associated with ESBL infections by reducing the number of inpatient bed days required for their successful treatment.Keywords
This publication has 10 references indexed in Scilit:
- Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum β-lactamaseJournal of Medical Microbiology, 2010
- In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: results from the SMART studyInternational Journal of Antimicrobial Agents, 2009
- Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspectiveJournal of Antimicrobial Chemotherapy, 2009
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Efficacy of Ertapenem for Consolidation Therapy of Extended-Spectrum β-lactamase-Producing Gram-Negative Infections: A Case Series ReportAnnals of Pharmacotherapy, 2008
- Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the communityJournal of Antimicrobial Chemotherapy, 2005
- In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)Journal of Antimicrobial Chemotherapy, 2005
- Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum -LactamasesClinical Infectious Diseases, 2004
- Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) ProgrammePharmacoEconomics, 2000
- Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogensAntimicrobial Agents and Chemotherapy, 1997